IS4813A - Benzyl iden-Lactam derivatives, their preparation and their use as selective antagonists for 5-HT1A and / or 5-HT1D receptors - Google Patents
Benzyl iden-Lactam derivatives, their preparation and their use as selective antagonists for 5-HT1A and / or 5-HT1D receptorsInfo
- Publication number
- IS4813A IS4813A IS4813A IS4813A IS4813A IS 4813 A IS4813 A IS 4813A IS 4813 A IS4813 A IS 4813A IS 4813 A IS4813 A IS 4813A IS 4813 A IS4813 A IS 4813A
- Authority
- IS
- Iceland
- Prior art keywords
- ht1a
- preparation
- selective antagonists
- lactam derivatives
- ht1d receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1513496P | 1996-03-29 | 1996-03-29 | |
PCT/IB1997/000076 WO1997036867A1 (en) | 1996-03-29 | 1997-02-03 | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IS4813A true IS4813A (en) | 1998-07-29 |
Family
ID=21769713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS4813A IS4813A (en) | 1996-03-29 | 1998-07-29 | Benzyl iden-Lactam derivatives, their preparation and their use as selective antagonists for 5-HT1A and / or 5-HT1D receptors |
Country Status (40)
Country | Link |
---|---|
US (2) | US6462048B2 (en) |
EP (1) | EP0894085B1 (en) |
JP (1) | JP3118467B2 (en) |
KR (1) | KR100305071B1 (en) |
CN (1) | CN1128788C (en) |
AP (1) | AP824A (en) |
AR (1) | AR006390A1 (en) |
AT (1) | ATE302182T1 (en) |
AU (1) | AU706839B2 (en) |
BG (1) | BG64176B1 (en) |
BR (1) | BR9708581A (en) |
CA (1) | CA2249603A1 (en) |
CO (1) | CO4650033A1 (en) |
CZ (1) | CZ293628B6 (en) |
DE (1) | DE69733996T2 (en) |
DZ (1) | DZ2198A1 (en) |
EA (1) | EA001485B1 (en) |
ES (1) | ES2246058T3 (en) |
HK (1) | HK1019446A1 (en) |
HN (1) | HN1997000023A (en) |
HR (1) | HRP970175A2 (en) |
HU (1) | HUP9902160A3 (en) |
ID (1) | ID17781A (en) |
IL (1) | IL125377A (en) |
IS (1) | IS4813A (en) |
MA (1) | MA26425A1 (en) |
MY (1) | MY118498A (en) |
NO (1) | NO312957B1 (en) |
NZ (1) | NZ325914A (en) |
OA (1) | OA10879A (en) |
PL (1) | PL329170A1 (en) |
SK (1) | SK131498A3 (en) |
TN (1) | TNSN97056A1 (en) |
TR (1) | TR199801929T2 (en) |
TW (1) | TW413679B (en) |
UA (1) | UA70284C2 (en) |
UY (1) | UY24498A1 (en) |
WO (1) | WO1997036867A1 (en) |
YU (1) | YU11997A (en) |
ZA (1) | ZA972690B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH041367U (en) * | 1990-04-13 | 1992-01-08 | ||
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US6906093B2 (en) | 1995-06-07 | 2005-06-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US6696448B2 (en) | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
DE19830201A1 (en) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Antidepressant |
CA2301899C (en) * | 1998-07-27 | 2008-11-18 | Boehringer Ingelheim Pharma Kg | Agent with an antidepressant activity |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US6492398B1 (en) | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
ES2225031T3 (en) * | 1999-12-29 | 2005-03-16 | Pfizer Products Inc. | COMPOUNDS OF 3 - ((2-PIPERAZINIL-PHENYL) METHYL) -1- (4- (TRIFLUOROMETIL) PHENYL) -2-OPTICALLY ACTIVE PIRROLIDINONE AS SELECTIVE ANTAGONISTS OF THE 5-HT1D RECEIVER. |
US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
EP1434774A1 (en) | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
PL372096A1 (en) | 2002-01-02 | 2005-07-11 | Ardent Pharmaceuticals, Inc. | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
DE602004028150D1 (en) * | 2003-11-26 | 2010-08-26 | Pfizer Prod Inc | AMINOPYRAZOL DERIVATIVES AS GSK-3 INHIBITORS |
CA2553291A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists |
JP4880583B2 (en) | 2004-03-17 | 2012-02-22 | ファイザー・プロダクツ・インク | Novel benzyl (benzylidene) -lactam derivatives |
BRPI0510942A (en) * | 2004-05-11 | 2007-07-17 | Pfizer Prod Inc | combination of atypical antipsychotics and 5-ht1b receptor antagonists |
BRPI0511419A (en) * | 2004-05-21 | 2007-12-04 | Pfizer Prod Inc | pyrazinylmethyl lactam derivative |
BRPI0512406A (en) * | 2004-06-25 | 2008-03-04 | Pfizer Prod Inc | pyridyl piperazine, pharmaceutical compositions comprising them and intermediate for the synthesis of pyridyl piperazine |
WO2006075226A1 (en) * | 2005-01-13 | 2006-07-20 | Pfizer Products Inc. | 11c-labeled benzyl-lactam compounds and their use as imaging agents |
WO2006106416A1 (en) * | 2005-04-08 | 2006-10-12 | Pfizer Products Inc. | PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN |
JP2008543829A (en) * | 2005-06-17 | 2008-12-04 | ファイザー・プロダクツ・インク | 1- [6- (1-Ethyl-1-hydroxy-propyl) -pyridin-3-yl] -3- [2- (4-methyl-piperazin-1-yl) -benzyl]-as a serotonin receptor antagonist Metabolites of pyrrolidin-2-one |
WO2007012964A1 (en) * | 2005-07-25 | 2007-02-01 | Pfizer Products Inc. | Preparation of alkylpiperazinylphenyl compounds by classical resolution |
WO2007026224A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | 5-ht1b antagonist composition for depression, anxiety and cognition |
WO2007026219A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
US20070096411A1 (en) * | 2005-11-02 | 2007-05-03 | Rempe Gary L Ii | Device for retaining a kneeling rider on a gliding board |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10246436B2 (en) * | 2015-09-02 | 2019-04-02 | Trevena, Inc. | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
JP7185633B2 (en) | 2017-02-17 | 2022-12-07 | トレベナ・インコーポレイテッド | Delta-Opioid Receptor Modulating Compounds Containing 7-Membered Azaheterocycles, Methods of Use and Preparation Thereof |
CN110520129A (en) | 2017-02-17 | 2019-11-29 | 特维娜有限公司 | Delta opiate receptor modulating compound and its use and preparation method containing 5 yuan of aza heterocycles |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078062A (en) | 1976-10-28 | 1978-03-07 | E. R. Squibb & Sons, Inc. | Substituted 2H-1,4-benzothiazin-3(4H)-ones |
JPS62116557A (en) * | 1985-11-15 | 1987-05-28 | Takeda Chem Ind Ltd | Substituted benzyl lactam |
US5189179A (en) * | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
ATE204262T1 (en) | 1991-09-18 | 2001-09-15 | Glaxo Group Ltd | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS |
WO1993007128A1 (en) * | 1991-10-11 | 1993-04-15 | The Du Pont Merck Pharmaceutical Company | Cyclic ureas and analogues useful as retroviral protease inhibitiors |
US5436246A (en) | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
-
1997
- 1997-02-03 BR BR9708581A patent/BR9708581A/en not_active Application Discontinuation
- 1997-02-03 TR TR1998/01929T patent/TR199801929T2/en unknown
- 1997-02-03 HU HU9902160A patent/HUP9902160A3/en unknown
- 1997-02-03 CA CA002249603A patent/CA2249603A1/en not_active Abandoned
- 1997-02-03 EA EA199800771A patent/EA001485B1/en not_active IP Right Cessation
- 1997-02-03 DE DE69733996T patent/DE69733996T2/en not_active Expired - Fee Related
- 1997-02-03 IL IL12537797A patent/IL125377A/en not_active IP Right Cessation
- 1997-02-03 SK SK1314-98A patent/SK131498A3/en unknown
- 1997-02-03 EP EP97900717A patent/EP0894085B1/en not_active Expired - Lifetime
- 1997-02-03 KR KR1019980707713A patent/KR100305071B1/en not_active IP Right Cessation
- 1997-02-03 JP JP09535074A patent/JP3118467B2/en not_active Expired - Fee Related
- 1997-02-03 PL PL97329170A patent/PL329170A1/en unknown
- 1997-02-03 CN CN97193251A patent/CN1128788C/en not_active Expired - Fee Related
- 1997-02-03 CZ CZ19983052A patent/CZ293628B6/en not_active IP Right Cessation
- 1997-02-03 ES ES97900717T patent/ES2246058T3/en not_active Expired - Lifetime
- 1997-02-03 WO PCT/IB1997/000076 patent/WO1997036867A1/en active IP Right Grant
- 1997-02-03 NZ NZ325914A patent/NZ325914A/en unknown
- 1997-02-03 AT AT97900717T patent/ATE302182T1/en not_active IP Right Cessation
- 1997-02-03 AU AU13170/97A patent/AU706839B2/en not_active Ceased
- 1997-02-03 US US09/155,215 patent/US6462048B2/en not_active Expired - Fee Related
- 1997-02-04 TW TW086101295A patent/TW413679B/en active
- 1997-02-06 HN HN1997000023A patent/HN1997000023A/en unknown
- 1997-03-02 UA UA98095077A patent/UA70284C2/en unknown
- 1997-03-13 CO CO97013714A patent/CO4650033A1/en unknown
- 1997-03-21 UY UY24498A patent/UY24498A1/en not_active IP Right Cessation
- 1997-03-25 AR ARP970101200A patent/AR006390A1/en not_active Application Discontinuation
- 1997-03-26 TN TNTNSN97056A patent/TNSN97056A1/en unknown
- 1997-03-26 DZ DZ970045A patent/DZ2198A1/en active
- 1997-03-26 HR HR60/015,134A patent/HRP970175A2/en not_active Application Discontinuation
- 1997-03-26 MA MA24535A patent/MA26425A1/en unknown
- 1997-03-27 ZA ZA972690A patent/ZA972690B/en unknown
- 1997-03-27 YU YU11997A patent/YU11997A/en unknown
- 1997-03-27 ID IDP971025A patent/ID17781A/en unknown
- 1997-03-27 AP APAP/P/1997/000955A patent/AP824A/en active
- 1997-03-28 MY MYPI97001340A patent/MY118498A/en unknown
-
1998
- 1998-07-29 IS IS4813A patent/IS4813A/en unknown
- 1998-09-16 OA OA9800170A patent/OA10879A/en unknown
- 1998-09-24 BG BG102791A patent/BG64176B1/en unknown
- 1998-09-28 NO NO19984513A patent/NO312957B1/en unknown
-
1999
- 1999-10-13 HK HK99104493A patent/HK1019446A1/en not_active IP Right Cessation
-
2002
- 2002-08-15 US US10/219,692 patent/US6924289B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS4813A (en) | Benzyl iden-Lactam derivatives, their preparation and their use as selective antagonists for 5-HT1A and / or 5-HT1D receptors | |
AU4337699A (en) | Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5HT4 receptors | |
IS2458B (en) | Indolin-2-one derivatives, their preparation and their use as ocytocin receptors | |
HK1084394A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use for preparing neurokinin antagonists | |
HK1042084A1 (en) | Substituted benzimidazoles and their preparation and use. | |
EE04721B1 (en) | Phenylxanthine derivatives, processes for their preparation and use | |
IT1313625B1 (en) | BENZIMIDAZOLONIC DERIVATIVES WITH MIXED AFFINITY FOR DYEROTONIN AND DOPAMIN RECEPTORS. | |
NO20021379D0 (en) | Benzodiazepine derivatives, preparation and use thereof | |
DK1119557T3 (en) | Indeno-, Naphtho- and Benzocyclohepta-dihydrothiazole derivatives, their preparation and their use as anorectic drugs | |
NO20006138D0 (en) | Substituted indolinones, preparation and use thereof as drugs | |
HK1030939A1 (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
NO996115L (en) | Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists | |
HUP0101475A3 (en) | 4,5,6 and 7-indole and indoline derivatives, their preparation and use | |
EE03682B1 (en) | Substituted benzimidazole derivatives, processes for their preparation and their use | |
DK0819703T3 (en) | Polymeric glucan ether derivatives, preparation and use thereof | |
NO971136D0 (en) | Aminoalkyl and acylaminoaclyl ether, process for its preparation and use as bradykinin receptor antagonists | |
HUP0100926A3 (en) | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists | |
NO963331D0 (en) | 5-Heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists | |
DK1025100T3 (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, their preparation and their use | |
DK1296961T3 (en) | 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists | |
ATE337321T1 (en) | CABAPENEM DERIVATIVES, THEIR USE AND THEIR INTERMEDIATE PRODUCTS | |
NO20014224L (en) | 4-heterocyclysulfonamidyl-6-methoxy-5- (2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, preparation thereof and use as endothelin receptor antagonists | |
NO992976L (en) | Heterocyclic carboxylic acid derivatives, preparation and use thereof as endothelin receptor antagonists | |
HUP0003758A3 (en) | 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) | |
PL344978A1 (en) | 4,5,6 and 7-indole and indoline derivatives, their preparation and use |